Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding

American Journal of Health-System Pharmacy

Volumn 56, Issue 23 SUPPL. 4, 1999, Pages

  Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti infective agents; Anti inflammatory agents; Combined therapy; Critical illness; Gastrointestinal drugs; Gastrointestinal hemorrhage; Helicobacter infections; Toxicity; Ulcers

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIMICROBIAL THERAPY; CONFERENCE PAPER; CRITICAL ILLNESS; DIGESTIVE SYSTEM HEMORRHAGE; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STRESS ULCER; UNITED STATES;

EID: 0033485678     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.suppl_4.s5     Document Type: Conference Paper

References (59)

1. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104.
2. National Institutes of Health Consensus Development Conference Statement. Helicobacter pylori in peptic ulcer disease. NIH Consens Statement. 1994; 12(1):1-23.
3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1:1311-5.
4. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995; 9(suppl 2):59-69.
5. Valle J, Kekki M, Sipponen P et al. Long-term course and consequences of Helicobacter pylori gastritis. Scand J Gastroenterol. 1996; 31:546-50.
6. Forman D, Webb P, Parsonnet J. Helicobacter pylori and gastric cancer. Lancet. 1994; 343:243-4.
7. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31.
8. Nomura A, Stemmermann GN, Chyou P et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6.
9. Tytgat GNJ, Noach IA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am. 1993; 22:127-40.
10. Laine L. Helicobacter pylori and complicated ulcer disease. Am J Med. 1996; 100:52S-9S.
11. Bayerdorffer E, Neubauer A, Morgner A et al. Regression of primary gastric low grade malt lymphoma after cure of Helicobacter pylori infection - German MALT lymphoma trial. Gastroenterology. 1996; 110(4, suppl):A490. Abstract.
12. Peura DA. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology. 1997; 113(suppl 1):S4-8.
13. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut. 1997; 41:8-13.
14. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol. 1997; 43:223-43.
15. Weissfeld A, Haber M, Rose P et al. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori. Gastroenterology. 1997; 112(4, suppl):A328. Abstract.
16. Graham DY, Hoffman J, El-Zimaity HMT et al. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11:935-8.
17. Schwartz H, Krause R, Sahba B et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol. 1998; 93:584-90.
18. Fennerty MB, Kovacs TOG, Krause R et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med. 1998; 158:1651-6.
19. Fennerty B, Bianchi T, Rose P et al. Triple therapy with lansoprazole, clarithromycin, and amoxicillin is highly effective in the eradication of Helicobacter pylori infection. Gastroenterology. 1997; 112(4, suppl):A116. Abstract.
20. Metz DC, Pound D, Rose P et al. Effects of smoking on Helicobacter pylori eradication regimens involving lansoprazole, amoxicillin, and clarithromycin. Gastroenterology. 1997; 112(4, suppl):A218. Abstract.
21. Lind T, Veldhuyzen van Zanten SJO, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH-1 Study. Helicobacter. 1996; 1:138-44.
22. Laine L, Estrada R, Truillo M et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996; 10: 1029-33.
23. Huang J-Q, Chiba N, Wilkinson JM et al. Which combination therapy can eradicate ≥ 90% Helicobacter pylori infection? A meta-analysis of amoxicillin, metronidazole, tetracycline, and clarithromycin containing regimens. Gastroenterology. 1997; 112(4, suppl):A19. Abstract.
24. Jyotheeswaran S, Shah AN, Jin HO et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol. 1998; 93:574-8.
25. Chey WD, Spybrook M, Carpenter S et al. Prolonged effect of omeprazole on the 14-C urea breath test. Am J Gastroenterol. 1996; 91:89-92.
26. Dieterich C, Wiesel P, Neiger R et al. Animal-human transmission of Helicobacter heilmannii - strain identity between a patient with gastric ulcer and one of his cats. Gut. 1997; 41(suppl 1):A124. Abstract.
27. Blum RA, Shi H, Karol MD et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther. 1997; 19:1013-23.
28. McColl KEL, El-Nujumi AM, Chittajalu RS et al. A study of the pathogenesis of Helicobacter pylori-negative duodenal ulceration. Gut. 1993; 34:762-8.
29. Lanza F, Goff J, Silvers D et al. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. Dig Dis Sci. 1997; 42:2529-36.
30. 2 antagonists in acute upper gastrointestinal hemorrhage. N Engl J Med. 1985; 313:660-6.
31. Daneshmend TK, Hawkey CJ, Langman MJS et al. Omeprazole versus placebo for acute gastrointestinal bleeding: randomized double blind controlled trial. Br Med J. 1992; 304: 143-7.
32. Lanas A, Artal A, Blas JM et al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol. 1995; 21:103-6.
33. Khuroo MS, Yattoo GN, Javid G et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med. 1997; 336:1054-8.
34. Lin HJ, Lo WC, Lee FY et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med. 1998; 158:54-8.
35. Costamagna G, Mutignani M, Perri V et al. Efficacy of i.v. lansoprazole in preventing bleeding relapse in upper gastrointestinal non-variceal bleeding. Gastroenterology. 1998; 114 (4, suppl):A95. Abstract.
36. Zeidler H. Epidemiology of NSAID induced gastropathy. J Rheumatol. 1991; 18(suppl 28):2-5.
37. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol. 1996; 91:2080-6.
38. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut. 1991; 32:252-5.
39. Hudson N, Taha AS, Russell RI et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997; 112:1817-22.
40. Bank S, Greenberg RE, Magier D et al. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Clin Ther. 1991; 13:304-18.
41. Walan A, Bader J-P, Classen M et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989; 320:69-75.
42. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med. 1998; 338:719-26.
43. Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med. 1998; 338:727-34.
44. Agrawal NM, Campbell DR, Safdi MA et al. Lansoprazole is superior to ranitidine in healing NSAID-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med. In press.
45. Rose P, Huang B, Lukasik N et al. Evidence that lansoprazole is effective in preventing NSAID induced ulcers. Gastroenterology. 1999; 116 (6, suppl):A295. Abstract.
46. Geus WP, Lamers CB. Prevention of stress ulcer bleeding: a review. Scand J Gastroenterol Suppl. 1990; 178:32-41.
47. Levine BA. Pathophysiology and mechanisms of stress ulcer injury. Pharmacotherapy. 1987; 7:90S-4S.
48. Cook DJ, Fuller HD, Guyatt GH et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994; 330:377-81.
49. Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med. 1987; 106:562-7.
50. Cook DJ, Witt LG, Cook RJ et al. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991; 91:519-27.
51. Peterson WL. Prevention of upper gastrointestinal bleeding. N Engl J Med. 1994; 330:428-9. Comment.
52. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997; 54:581-96.
53. Zinner MJ, Zuidema GD, Smith PL et al. The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet. 1981; 153:214-20.
54. Tryba M, Huchzermeyer H, Torok M et al. Single drug and combined medication with cimetidine, antacids, and pirenzepine in the prophylaxis of acute gastrointestinal bleeding. Hepatogastroenterology. 1983; 30:154-7.
55. Navab F, Steingrub J. Stress ulcer prophylaxis: is routine prophylaxis necessary? Am J Gastroenterol. 1995; 90:708-12.
56. Fiddian-Green RG, McGough E, Pittenger G et al. Predictive value of intramural pH and other risk factors for massive bleeding from stress ulceration. Gastroenterology. 1983; 85: 613-20.
57. Peura DA. Recognizing, setting therapeutic goals, and selecting therapy for the prevention and treatment of stress-related mucosal damage. Pharmacotherapy. 1987; 7(6, suppl):95S-103S.
58. Phillips JO, Metzler MH, Palmieri TL et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996; 24:1793-1800.
59. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998; 44:527-33.